Ding Lin, Mo Huaqian, Yang Yaping, Li Qingjian, Bi Zhuofei
Department of Radiation Oncology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China.
Breast Tumor Center, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China.
Gland Surg. 2025 Jun 30;14(6):1012-1023. doi: 10.21037/gs-2025-52. Epub 2025 Jun 26.
Breast-conserving surgery (BCS) followed by adjuvant whole-breast external beam radiotherapy (WBRT) is a standard treatment for early-stage breast cancer, effectively reducing local recurrence and improving survival. However, WBRT involves a prolonged treatment schedule and may lead to adverse effects and reduced patient compliance. Intraoperative radiotherapy (IORT), as a form of accelerated partial breast irradiation (APBI), offers a shorter treatment course by delivering a single dose of radiation during surgery. Although randomized controlled trials suggest comparable survival outcomes between IORT and WBRT in selected patients, real-world evidence is limited. This study aimed to compare the effects of IORT and WBRT on survival outcomes in early-stage breast cancer patients who underwent BCS, using a population-based dataset.
Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2019. Patients who received either IORT or WBRT after BCS were included. Overall survival (OS) and cancer-specific survival (CSS) were assessed using Kaplan-Meier methods. Cox proportional hazards regression was performed to identify independent prognostic factors.
There was no statistically significant difference in OS and CSS between the IORT and WBRT groups. Factors associated with worse survival included older age, T2 stage, and higher tumor grade (all P<0.01). Positive estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status were significantly associated with improved survival (all P<0.01).
IORT is an effective alternative to WBRT with equivalent long-term survival. IORT may be considered for eligible patients based on age, tumor size, receptor status, and grade. Prospective studies are warranted to optimize the selection criteria.
保乳手术(BCS)联合辅助全乳外照射放疗(WBRT)是早期乳腺癌的标准治疗方法,可有效降低局部复发率并提高生存率。然而,WBRT治疗疗程较长,可能导致不良反应并降低患者依从性。术中放疗(IORT)作为加速部分乳腺照射(APBI)的一种形式,通过在手术期间给予单次辐射剂量,提供了更短的治疗疗程。尽管随机对照试验表明,在选定患者中IORT和WBRT的生存结果相当,但实际证据有限。本研究旨在使用基于人群的数据集,比较IORT和WBRT对接受BCS的早期乳腺癌患者生存结果的影响。
从2010年至2019年的监测、流行病学和最终结果(SEER)数据库中提取数据。纳入BCS术后接受IORT或WBRT的患者。采用Kaplan-Meier方法评估总生存期(OS)和癌症特异性生存期(CSS)。进行Cox比例风险回归以确定独立的预后因素。
IORT组和WBRT组的OS和CSS无统计学显著差异。与较差生存相关的因素包括年龄较大、T2期和较高的肿瘤分级(均P<0.01)。雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)阳性状态与生存改善显著相关(均P<0.01)。
IORT是WBRT的有效替代方案,具有相当的长期生存率。可根据年龄、肿瘤大小、受体状态和分级,考虑对符合条件的患者采用IORT。有必要进行前瞻性研究以优化选择标准。